{
  "id": "IF12700",
  "type": "CRS In Focus",
  "typeId": "IF",
  "number": "IF12700",
  "active": true,
  "source": "CRSReports.Congress.gov",
  "versions": [
    {
      "source_dir": "crsreports.congress.gov",
      "title": "\u201cSkinny Labels\u201d for Generic Drugs Under Hatch-Waxman",
      "retrieved": "2024-08-01T04:04:08.820183",
      "id": "IF12700_1_2024-07-01",
      "formats": [
        {
          "filename": "files/2024-07-01_IF12700_d4bbcc44195b4d63b6961e1ce4c09b2ec2e40030.pdf",
          "format": "PDF",
          "url": "https://crsreports.congress.gov/product/pdf/IF/IF12700/1",
          "sha1": "d4bbcc44195b4d63b6961e1ce4c09b2ec2e40030"
        },
        {
          "format": "HTML",
          "filename": "files/2024-07-01_IF12700_d4bbcc44195b4d63b6961e1ce4c09b2ec2e40030.html"
        }
      ],
      "date": "2024-07-01",
      "summary": null,
      "source": "CRSReports.Congress.gov",
      "typeId": "IF",
      "active": true,
      "sourceLink": "https://crsreports.congress.gov/product/details?prodcode=IF12700",
      "type": "CRS In Focus"
    }
  ],
  "topics": []
}